Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29161252 | 0.83 | FFAR1 (0.35) | FFAR1 | |
| SCHEMBL21812834 | 0.78 | CYP4F2 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL1534508 | 0.76 | CD274 (0.35) | CYP4F2CYP4A11GAACYP2C19 | |
| SCHEMBL24947688 | 0.76 | CYP4F2 (0.35) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL25416797 | 0.74 | GAA (0.38) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL760525 | 0.74 | FFAR1 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL31488070 | 0.74 | FFAR1 (0.42) | CYP4F2CYP4A11ALDH1A1LMNAPOLB | |
| SCHEMBL23693245 | 0.74 | CYP2C19 (0.36) | CYP4F2CYP4A11ALDH1A1CYP2C19 | |
| SCHEMBL30971332 | 0.74 | P2RX7 (0.32) | CYP4F2CYP4A11CYP2C19 | |
| SCHEMBL3401227 | 0.73 | ALDH1A1 (0.39) | CYP4F2CYP4A11ALDH1A1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731207-A2 | INHIBITORS OF HUMAN RESPIRATORY SYNCYTIAL VIRUS AND METAPNEUMOVIRUS | Merck Sharp & Dohme LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| WO-2025264700-A1 | GIP RECEPTOR AGONIST COMPOUNDS | ELI LILLY AND COMPANY (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264959-A1 | SUBSTITUTED PYRAZOLOPYRIDINES AS PHOSPHOINOSIDIDE KINASE (PIK) MODULATORS | RECURSION PHARMACEUTICALS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| EP-4652154-A1 | NOVEL ALPK1 INHIBITORS | Pyrotech (Beijing) Biotechnology Co., Ltd. (CN) | 2025-11-26 | — | — | EP | disclosed |
| EP-4594318-A1 | AKT1 MODULATORS | Alterome Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | D. E. SHAW RESEARCH, LLC | 2025-05-15 | — | — | US | disclosed |
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025036241-A1 | COMPOUNDS AND METHODS FOR MODULATING RNA SPLICING | RIBOPEUTIC INC. (CN) | 2025-02-20 | — | — | WO | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2019-03-07 | — | — | US | disclosed |
| EP-3419978-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | Pfizer Inc (US) | 2019-01-02 | — | — | EP | disclosed |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | PFIZER INC. (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018217439-A1 | SUBSTITUTED [5,6]CYCLIC-4(3H)-PYRIMIDINONES AS ANTICANCER AGENTS | ZHANG HAI JUN (US) | 2018-11-29 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017144995-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES AS JAK-INHIBITORS | PFIZER INC. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | PFIZER INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074881-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | CYP4F2 3373/4885CYP4A11 2629/4885ALDH1A1 829/4885 |
| US-10144738-B2 | Pyrazolo[1,5-A]PYRAZIN-4-YL derivatives | JAK1, JAK2, JAK3 | CYP4F2 2282/4885CYP4A11 670/4885ALDH1A1 1666/4885 |
| US-20170240552-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CYP4F2 502/4885CYP4A11 284/4885ALDH1A1 3564/4885 |
| US-20250154139-A1 | PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS | TRPA1, TRPV1, TRPV5 | CYP4F2 440/4885CYP4A11 699/4885ALDH1A1 538/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | CYP4F2 1758/4885CYP4A11 558/4885ALDH1A1 2982/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | CYP4F2 4667/4885CYP4A11 3700/4885ALDH1A1 4692/4885 |
| US-20190071448-A1 | PYRAZOLO[1,5-A]PYRAZIN-4-YL DERIVATIVES | CBR3, CNR1, CCR6 | CYP4F2 502/4885CYP4A11 284/4885ALDH1A1 3564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.